Component, content:
Carmustine 100mgDosage form, administration:
Powder and diluent. Carmustine for injection.
Indications:
BiCNU is indicated as palliative therapy as a single agent or in established combination therapy with
other approved chemotherapeutic agents in the following:
1. Brain tumors—glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma,
and metastatic brain tumors.
2. Multiple myeloma—in combination with prednisone.
3. Hodgkin’s Disease—as secondary therapy in combination with other approved drugs in patients
who relapse while being treated with primary therapy, or who fail to respond to primary therapy.
4. Non-Hodgkin’s lymphomas—as secondary therapy in combination with other approved drugs for
patients who relapse while being treated with primary therapy, or who fail to respond to primary
therapy.
